Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 47,814 Shares

Key Points

• Director Peter Thompson sold 47,814 shares on April 14 at an average price of $44.51 for about $2.13M, trimming his stake by 1.35% to 3,482,888 shares; the transaction was executed under a pre-arranged Rule 10b5-1 plan.
• Sionna's stock traded at $45.24 (up $0.15) with a 1‑year range of $9.39–$46.10 and 50/200‑day moving averages near $37.40/$38.18, while analysts hold a "Moderate Buy" consensus with an average price target of $50.57.
• Institutional interest is rising, with new positions by Goldman Sachs and Woodline Partners and Geode Capital boosting its stake (up 113.4%), signaling growing institutional accumulation.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 47,814 shares of Sionna Therapeutics stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14. Following the sale, the director directly owned 3,482,888 shares of the company's stock, valued at approximately $155,023,344.88. This represents a 1.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock traded up $0.15 on Thursday, hitting $45.24. The company's stock had a trading volume of 817,609 shares, compared to its average volume of 382,339. Sionna Therapeutics, Inc. has a 1 year low of $9.39 and a 1 year high of $46.10. The firm has a fifty day moving average price of $37.40 and a 200-day moving average price of $38.18.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.15.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Citizens Jmp assumed coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They set a "market outperform" rating and a $63.00 price objective for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. BTIG Research reiterated a "buy" rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research note on Monday, March 2nd. UBS Group reiterated a "buy" rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Finally, Guggenheim boosted their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Sionna Therapeutics has an average rating of "Moderate Buy" and an average target price of $50.57.

Institutional Investors Weigh In On Sionna Therapeutics

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth approximately $667,000. Woodline Partners LP acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth approximately $837,000. Geode Capital Management LLC boosted its holdings in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $307,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $118,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.